Enter Your Email Address to Receive a
Copy of MedicExhange Member Demograhpics

AngioDynamics announced that it has appointed Shawn P. McCarthy as Senior Vice President and General Manager of the Company’s Peripheral Vascular Business Unit

AngioDynamics, Inc. (NASDAQ:ANGO), a leading provider of innovative medical devices for the minimally-invasive treatment of cancer and peripheral vascular disease, announced that it has appointed Shawn P. McCarthy, 40, as Senior Vice President and General Manager of the Company’s Peripheral Vascular Business Unit. Mr. McCarthy will report to Jan Keltjens, Chief Executive Officer of AngioDynamics.

“Shawn brings global leadership experiences across critical functions, managing product platforms in multiple companies and countries. He has a track record of successfully commercializing new products in important therapeutic areas, in highly regulated medical device markets,” said Mr. Keltjens. “Shawn possesses a deep customer understanding with significant success in marketing and sales. By joining our team he continues to build our capabilities in the marketplace and increase our capacity for future growth.”

Mr. McCarthy has more than 18 years of medical device commercial experience, with his last 10 years being at Johnson & Johnson. He began his career at Johnson & Johnson in 1998, as a product director for Cordis Corporation. He has held sales and marketing positions of increasing responsibility, ultimately leading to his most recent role as Vice President of Marketing at Cordis for their Endovascular and Cardiology divisions. Prior to joining Johnson & Johnson, Mr. McCarthy was the Senior Global Product Manager for the Respiratory Division of Sunrise Medical, Inc. He received his B.A. and M.B.A. from Syracuse University.

“I am looking forward to building on our position as the leader in the endovenous laser market, leveraging the strength of our VenaCure EVLT brand, our broader vein interventional business, as well as exciting new therapies such as our Benephit® system for targeted renal drug delivery,” said Mr. McCarthy. “We expect to continue advancing our relationships with physicians to deliver the best therapies available for their patients. I am committed to creating value for them, our employees, and our shareholders.”

Mr. McCarthy will relocate to upstate New York where he will join AngioDynamics on August 17. He replaces Sean Morris, who has served as SVP and GM of the Peripheral Vascular Unit since June 2008. Mr. Morris has agreed to assist during the transition period and will leave the Company when the transition is complete. “I would like to thank Sean Morris for his important contributions to AngioDynamics during his nine years of service and wish him the very best in the future,” said Mr. Keltjens.

About AngioDynamics

AngioDynamics, Inc. (“AngioDynamics” or the “Company”) is a leading provider of innovative medical devices used by interventional radiologists, surgeons and other physicians for the minimally-invasive treatment of cancer and peripheral vascular disease. The Company’s diverse product line includes market-leading radiofrequency and irreversible electroporation ablation systems, vascular access products, angiographic products and accessories, dialysis products, angioplasty products, drainage products, thrombolytic products, embolization products and venous products. More information is available at www.angiodynamics.com.

Source: AngioDynamics